BioSpace News Archive

ReCor Medical, Inc., a wholly-owned subsidiary of Otsuka Medical Devices, announced that its Paradise™ Ultrasound Renal Denervation System demonstrated positive results in the RADIANCE-HTN TRIO study, and, separately, has received Breakthrough Device Designation from the U.S. Food and Drug Administration for the treatment of patients with uncontrolled hypertension who are inadequately responsive to anti-hypertensive medications.

Advanced Bionics, a global leader in cochlear implant technology, in collaboration with Phonak, a leading provider of life-changing hearing solutions, receives FDA approval and announces it is bringing Marvel hearing technology to Advanced Bionics cochlear implant wearers.

Swedish Orphan Biovitrum AB announced that a Marketing Authorization Application for emapalumab has been accepted for review in China.

Crescendo Biologics Ltd, the drug developer of novel, targeted T cell enhancing therapeutics, announced that it has expanded its global, multi-target discovery and development collaboration with Takeda Pharmaceutical Company Limited after Crescendo achieved its sixth technical milestone.

Biofidelity Ltd, the cancer diagnostics company, announces the further expansion of its leadership team with the appointment of Dr. Robert Osborne as Chief Operating Officer.

The biomarkers for the real-time assessment of kidney function (penKid(R)) and endothelial function (bio-ADM(R)) are pioneering new diagnostic pathways in critical care settings

Advanced MedTech Holdings (AMTH), a global medical technology leader headquartered in Singapore, announced today that the RESOLUTE 2.0 test kit has become the first RT-PCR COVID-19 test to be authorised by Singapore’s Health Sciences Authority (HSA) for deep-throat saliva (DTS) SARS-CoV-2 testing.

Distinguished Academic and Industry Leaders in Oncology & Immunology to Advise Company’s Research and Development

Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increasefrom baseline of 2.7g/dLat Week 48, which isequal tothe2.7 g/dL increaseseen at Week 16 with pegcetacoplan-treated patients

International medical imaging IT and cybersecurity company Sectra has secured an enterprise imaging contract from the South-Eastern Norway Regional Health Authority.